Abstract: This tool is for treating an excised end of a body organ and is provided with: a long and thin, flexible first band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; a long and thin, flexible second band section having a distal end and a proximal end that are made of a biodegradable-absorptive polymer; and a first locking section having a first ratchet claw made of a biodegradable-absorptive polymer, wherein the first locking section is formed at the distal end of the second band section, the distal end of the first band section and the proximal end of the second band section are joined together, at least one ratchet tooth that is capable of meshing with the first ratchet claw is formed on the external surface of the first band section, and the engagement of the ratchet tooth with the first ratchet claw forms a flattened ring which is used to bind a body organ so as to ligate a tube or cavity that opens at an excised end of the body organ.

Abstract: Provided is a technique for computing a brain function index for diagnosing a mental disorder at the individual level, which can be applied to even a child around school age. A brain function index computing device includes a brain activity value calculation processing unit configured to calculate from brain activity signals of a subject a first brain activity value of a region including the meddle frontal gyrus (MFG) and a second brain activity value of a region including the inferior frontal gyrus (IFG); and a brain function index calculation processing unit configured to calculate a brain function index associated with a mental disorder using the first brain activity value and the second brain activity value.

Abstract: A means for substantially improving mitochondrial dysfunction is provided. An aspect of the present invention relates to an agent for improving mitochondrial dysfunction, having a compound represented by the following formula, a stereoisomer or a salt thereof, or a solvate thereof, as an active ingredient. Another aspect of the present invention relates to a medicament or a pharmaceutical composition having the aforementioned compound, a stereoisomer or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, as an active ingredient, for use in preventing or treating a disease or symptom caused by mitochondrial dysfunction.

Abstract: The present invention provides a means for transferring a therapeutic gene of interest into a nervous system cell by a highly-efficient and simpler means. More specifically, the present invention provides a recombinant vector that uses an adeno-associated virus (AAV), a method for manufacturing the recombinant vector, and a method for using the recombinant vector. More specifically, recombinant adeno-associated virus virions, which are capable of passing through the brain-brain barrier, for transferring a therapeutic genes of interest into a nervous system cell in a highly-efficient manner, a drug composition containing the recombinant adeno-associated virus virions, a method for manufacturing the recombinant adeno-associated virus virions, and a kit or the like are provided.

Abstract: The present invention provides a means for transferring a therapeutic gene of interest into a nervous system cell by a highly-efficient and simpler means. More specifically, the present invention provides a recombinant vector that uses an adeno-associated virus (AAV), a method for manufacturing the recombinant vector, and a method for using the recombinant vector. More specifically, recombinant adeno-associated virus virions, which are capable of passing through the brain-brain barrier, for transferring a therapeutic genes of interest into a nervous system cell in a highly-efficient manner, a drug composition containing the recombinant adeno-associated virus virions, a method for manufacturing the recombinant adeno-associated virus virions, and a kit or the like are provided.

Abstract: A method for assisting corneal severity identification, the method comprising obtaining a corneal configuration data set of a cornea to be examined by a tomography such as an optical coherence tomography; visualizing the corneal configuration data set of the cornea to be examined along with a number of pre-existing corneal configuration data sets of disorder corneas, disorder-suspect corneas and normal corneas obtained by the tomography using t-distributed Stochastic Neighbor Embedding in a two or three dimensional map, and judging corneal severity from the map.

Abstract: The purpose of the present invention is to adsorb calciprotein particles. An adsorbent for calciprotein particles of the present invention is characterized in that the surface of a water-insoluble carrier is covalently bonded, through a hydrocarbon group, to at least one selected from the group consisting of amino group, carboxyl group, phosphate group, phosphono group, phosphino group, and thiol group.

Abstract: An information management system includes: a mobile communication terminal capable of obtaining location information; and a medical institution provided with a regional medical data bank system and a transmitter. The mobile communication terminal transmits a space-time tag and a terminal ID to the system. The space-time tag is constituted of time information and location information. A space-time ID information processing unit of the system generates a space-time ID in a folder for each user based on a plurality of space-time tags and stores it in space-time ID information DB. A terminal device of the medical institution transmits the location information of the mobile communication terminal and the time information to the system. A verification processing unit verifies information from the mobile communication terminal against information from a utilization terminal and transmits the information to the utilization terminal when a request for transmission of the information is valid.

Abstract: Provided is a novel gene therapy means for neurological diseases including epilepsy. The present invention provides: a recombinant adeno-associated virus vector for use in the treatment of neurological diseases including epilepsy, which comprises a polynucleotide encoding a protein capable of improving the excitation-inhibiting function of an inhibitory synapse in vivo, preferably neuroligin-2 protein; a pharmaceutical composition comprising said recombinant vector; and others. The present invention also provides a method for treating a disease such as epilepsy using the recombinant vector.

Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.

Abstract: An object of the present invention is to provide a GLP-1 secretagogue which is an incretin hormone-related drug relatively inexpensive, excellent in safety, and capable of promoting GLP-1 secretion without containing sucrose as an essential constituent. The object is achieved by a GLP-1 secretagogue characterized by containing D-psicose as an active ingredient.

Abstract: The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof.

Abstract: Object: To provide an agent for sustaining satiety or a method for sustaining satiety, with which an individual's food intake is reduced by sustaining satiety, and as a result, pathological conditions such as obesity due to overeating can be prevented and improved. Means for Resolution: An agent for sustaining satiety containing D-psicose as an active ingredient and a method for sustaining satiety by the ingestion of D-psicose. Advantageous Effect: Satiety can be sustained although the increase in blood glucose level after eating is suppressed. A means for sustaining satiety which is useful for those who are anxious about their blood glucose level and those who are health conscious can be provided.

Abstract: An information management system includes: a mobile communication terminal capable of obtaining location information; and a medical institution provided with a regional medical data bank system and a transmitter. The mobile communication terminal transmits a space-time tag and a terminal ID to the system. The space-time tag is constituted of time information and location information. A space-time ID information processing unit of the system generates a space-time ID in a folder for each user based on a plurality of space-time tags and stores it in space-time ID information DB. A terminal device of the medical institution transmits the location information of the mobile communication terminal and the time information to the system. A verification processing unit verifies information from the mobile communication terminal against information from a utilization terminal and transmits the information to the utilization terminal when a request for transmission of the information is valid.

Abstract: The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients.

Abstract: The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients.

Abstract: [Problem] The present invention provides a novel pathological marker of angiitis which serves as an alternative to MPO-ANCAs. [Means for Solution] According to one embodiment of the present invention, a method for testing angiitis which includes a step of detecting an antibody specifically recognizing a moesin in a biological sample is provided. In addition, according to another embodiment of the present invention, a reagent for testing angiitis which contains a substance that detects an antibody specifically recognizing a moesin in a biological sample is provided.

Abstract: A treatment instrument for an endoscope is provided that is suitable for cutting submucosa in endoscopic submucosal dissection. The treatment instrument for an endoscope includes a treatment portion having a cutting unit at a tip of an insertion portion that is to be inserted into the body. The main unit of the treatment portion is formed in a sawtooth shape having a peak portion and a valley portion. An electrode plate serving as the cutting unit is provided in the valley portion.

Abstract: Polynucleotides which are novel causative genes for cancer are elucidated, and a detection method of the polynucleotides or polypeptides encoded by the polynucleotides, and a kit and a primer set for detection are provided, based on the knowledge gained by the elucidation. In the detection method, a fusion gene comprising part of an SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 gene and part of a ROS1 gene, or a fusion protein encoded by the fusion gene is detected. The primer set or the detection kit comprises a sense primer designed based on a portion encoding SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 and an antisense primer designed based on a portion encoding ROS1.

Abstract: A blood pressure measurement device includes a finger cuff for measuring a blood oxygen saturation level of a subject as physiological information excluding a blood pressure, a pulse wave detecting portion, and an oxygen saturation level calculating portion, where a start of blood pressure measurement in a sphygmomanometer is determined by a comparing and determining portion when a value becomes greater than or equal to a reference value. After the end of the measurement, a time limit for limiting the start of the blood pressure measurement is set. The comparing and determining portion determines not to start the blood pressure measurement within the time limit even if the blood oxygen saturation level becomes greater than or equal to the reference value.